Pharmacokinetic Study of HRS-4729 in Healthy Participants and Patients With Renal Impairment

Phase 1, open-label trial of HRS-4729 in Overweight, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and 2 more (4 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration up to 4 weeks, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration up to 4 weeks and 1 more. Started Sep 2026; status: recruiting.